The diversity of angiogenesis in diabetic vascular complications by Drela, Ewelina et al.
53www.fmc.viamedica.pl
Ewelina Drela, Arleta Kulwas, Barbara Ruszkowska, Danuta Rość
Department of Pathophysiology, Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus in Torun, Poland
The diversity of angiogenesis in diabetic 
vascular complications
ABSTRACT
Diabetes is one of the major healthcare problems and it is considered a global epidemic of the 21st 
century. Long lasting hyperglycaemia contributes to the development of vascular diabetic complications 
such as retinopathy, nephropathy or diabetic foot syndrome (DFS). The pathogenesis of each diabetic 
complication is multifactorial. Nevertheless, impaired angiogenesis is one potential component that might 
be common for many diabetic complications. Angiogenesis is a multi-stage process involving the endo-
thelium, growth factors and their inhibitors, cytokines, endothelial progenitor cells (EPCs) and enzymes. As 
far as angiogenesis is concerned, diabetes is a paradoxical disease. An excessive angiogenesis is noted 
in retinopathy or nephropathy, while in diabetic foot syndrome the angiogenic response is insufficient.
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Introduction
Modern medicine deals with neurodegenerative and 
cardiovascular diseases increasingly well. After years of 
high mortality because of heart diseases, now it is time 
to focus on metabolic disorders, among which diabetes, 
especially type 2 diabetes mellitus (T2DM), has been 
playing the key role for centuries. 
Since the beginning of this century, an epidemic, or 
even a pandemic, of diabetes has been observed. Type 
2 diabetes has become one of the most life-threatening 
metabolic diseases for two reasons. Firstly, increasing 
hyperglycaemia and insulin resistance remain asymp-
tomatic for a long time. The dysfunction of as much as 
50% of pancreatic beta cells induces a clinical mani-
festation. Secondly, untreated or wrongly controlled 
diabetes contributes to the development of micro- and 
macroangiopathies that significantly reduce the quality 
of a patient’s life [1]. The vascular complications of 
diabetes may include retinopathy, nephropathy and 
diabetic foot syndrome (DFS).
Retinopathy is the leading cause of blindness in the 
population in developed countries [2]. Nephropathy 
often leads to renal failure [3]. Amputations, which 
involve a high risk of mortality, are performed more of-
ten in patients with DFS than non-diabetic patients [4]. 
Thus, the development of diabetic vascular compli-
cations is a huge social and economic, and above all 
medical, challenge. Understanding the molecular basis 
of microangiopathy may be the key to the selection of 
appropriate therapy, because vascular complications 
are rarely found selectively.
Vascular complications of diabetes
Retinopathy
Diabetic retinopathy (DR) is one of the complications 
of long-lasting and poorly controlled diabetes. Accord-
ing to the World Health Organisation (WHO), 150 million 
people around the world suffer from retinopathy, and 
by 2025 this number is expected to have doubled [5]. 
The epidemiological data indicates that DR develops 
in 60% of patients with type 2 diabetes that has lasted 
for more than 20 years, and in the majority of patients 
with type 1 diabetes. Taking the presence/absence 
of abnormal new blood vessels as a criterion, there 
are three DR characters: nonproliferative retinopathy, 
proliferative retinopathy and macular oedema [2, 5]. 
Pathologic changes occur in the retina, but at more 
advanced stages of the disease they may include other 
parts of the eye (iris, angle of the eye) [2, 5]. Retinopathy 
is characterised by excessive growth of blood vessels 
with increased permeability [5]. Hyperglycaemia plays 
an important role in the pathogenesis of diabetic ret-
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inopathy. It activates the polyol metabolic pathway, 
generates oxidative stress, activates protein kinase C 
and leads to the production of advanced glycation end 
products (AGEs) [6–8]. All changes taking place under 
the influence of hyperglycaemia lead to abnormal blood 
vessel formation. Excessive formation of immature 
blood vessels induced by vascular endothelial growth 
factor (VEGF) is the major disorder in the pathogenesis 
of diabetic retinopathy.
Nephropathy 
Kidneys are also under the toxic effect of hyper-
glycaemia. Diabetic nephropathy is the most common 
cause of end stage renal disease in diabetic patients 
[9]. The risk of chronic kidney disease is higher in 
patients with type 1 diabetes, but paradoxically more 
nephropathy patients are encountered in the population 
of type 2 diabetes. 
Similarly, as in retinopathy, the mechanisms leading 
to the development of nephropathy are complex. Kidney 
damage in patients with diabetes is caused by haemo-
dynamic and metabolic changes. Ischaemia, hypoxia, 
hypertension, oxidative stress, hyperlipidaemia, chronic 
inflammation, and hyperglycaemia lead to extracellular 
and intracellular changes in the function and structure 
of the kidney [10, 11].
Diabetic nephropathy is characterised by glomerular 
hyperfiltration, increased vascular permeability, alteration 
within the basement membrane of the capillaries, and me-
sangial proliferation. The growth factors VEGF, TGF beta 
(transforming growth factor beta), PDGF (platelet derived 
growth factor) and enzymes (heparanase) are involved 
in the pathogenesis of diabetic nephropathy [12, 13,]. 
Adaptive changes at the early stages of nephropathy in-
volving the secretion of angiogenic factors (mainly VEGF) 
only initiate the process of angiogenesis, and they are 
the first step towards the degeneration of kidneys [11], 
which once started cannot be stopped. Risk factors 
such as smoking, obesity, and genetics may alter the 
rate of progression of nephropathy [9], so it is extremely 
important to select the correct treatment, as treatment 
may influence disease progression. Strict control of 
blood pressure, good diabetes control and adequate 
pharmacotherapy (medicines of the renin-angiotensin 
system (RAS), angiotensin converting enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs)) may 
slow the changes in the kidney [3].
Diabetic foot syndrome
It is believed that diabetic foot syndrome (DFS) is 
the most medically and socio-economically devastating 
complication of diabetes. DFS significantly increases 
mortality in diabetic patients [10]. The high mortality 
is associated with the development of non-healing 
wounds, which are caused by neuropathy, progressive 
ischaemia and impaired angiogenesis [14]. Wound 
contamination by bacteria, which leads to non-healing 
ulcers, is the factor increasing the mortality rate in pa-
tients with DFS. According to the International Diabetes 
Federation (IDF), each year nearly 4 million ulcers are 
diagnosed [15–17]. Diabetic foot ulcers represent 84% of 
all lower limb amputations [10]. Interestingly, DFS devel-
ops also in patients with newly diagnosed diabetes [10]. 
Abnormal angiogenesis plays the main role in the 
pathogenesis of DFS. It impairs the phase of migration 
and proliferation of cells. Wound healing consists of four 
phases: coagulation, inflammation, migration with pro-
liferation, and remodelling. Angiogenesis occurs during 
the migration and proliferation phase of the wound heal-
ing process [14]. The formation of normal blood vessels 
is a critical point during the healing process, because of 
supplying the surrounding tissue with oxygen. Abnormal 
vascular structures are not able to provide optimal blood 
supply, resulting in an increase of hypoxia. Progressive 
ischaemia and hypoxia lead to tissue necrosis. 
The aetiology of microangiopathy is different and 
multifactorial, but a common component of vascular dia-
betic complications might be the abnormal angiogenesis.
Angiogenesis in the diabetic vascular 
complications
Physiological angiogenesis is a process of interac-
tion between specific factors, cytokines, enzymes and 
cells, whose appearance at the appropriate concen-
tration, quantity and time results in new blood vessels 
formation. Despite the complexity of this process, 
some steps can be identified: increase of the perme-
ability of existing vessels, stimulation of endothelial cells 
(ECs morphological change), the degradation of the 
extracellular matrix, the migration and proliferation of 
endothelial cells (tubule vessel formation), the matura-
tion of new blood vessels (stabilisation by pericytes 
and establishment of intercellular connections) [11, 15]. 
A balance between angiogenesis stimulators and in-
hibitors ensures that new, properly functioning blood 
vessels form. The deterioration of this balance leads 
to an excessive vascularisation or to insufficient blood 
vessel formation. Abnormal angiogenesis occurs in 
many pathological conditions such as cancer, impaired 
wound healing, and cardiovascular diseases [10]. 
Diabetes, which is a metabolic disorder, is extremely 
fascinating from the angiogenic point of view. This is 
because of the development of diabetic vascular com-
plications, where abnormal formation of blood vessels 
plays a key role in the pathogenesis. Hypoxia, which is 
caused by hyperglycaemia, may develop. The effects 
of angiogenesis, as a result of hypoxia, are different in 
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various organs. Thus, impaired angiogenesis may lead 
to excessive formation of blood vessels with increased 
permeability in the eye (retinopathy), increased perme-
ability of blood vessels in the kidneys (nephropathy), 
and insufficient vessel formation in hypoxic tissues 
during the healing process (diabetic foot syndrome). 
Vascular endothelial growth factor (VEGF) is the 
best known regulator of angiogenesis. The increased 
concentration of this factor has been observed in the 
vitreous in patients with proliferative diabetic retinopathy 
(PDR) [7, 17]. Studies have shown that serum VEGF lev-
els vary with changes in the progression of retinopathy. 
Ozturk et al. observed a higher concentration of VEGF 
in the serum of patients with nonproliferative retinopathy 
compared to a group with PDR. In this study, significant 
correlations between serum VEGF and the duration of 
diabetes and the cytokines IL-1a, IL-6 were noted [18].
Raised VEGF expression is also observed in diabetic 
nephropathy, but only at the early stages of the disease. 
Studies in animal models [19, 20] suggest that the level 
of VEGF decreases with progressive renal injury. Similar 
results were reported by Bortoloso et al. in patients with 
type 2 diabetes [21]. This study showed a negative 
correlation between glomerular mRNA VEGF and AER 
(albumin excretion rate) and the relationship of VEGF 
and mRNA VEGF-R2 (vascular endothelial growth factor 
receptor 2). However, there was no relationship be-
tween VEGF and VEGF-R1 (vascular endothelial growth 
factor receptor 1). [21]. The increased expression of 
VEGF at the initial stages of nephropathy may be the 
result of toxic effects of hyperglycaemia and glomerular 
hypertension. It seems that at this stage the increased 
VEGF secretion has a protective function. However, 
initiated angiogenesis contributes to the destruction of 
renal structures. Damaged podocytes and endothelial 
cells (the major source of VEGF in the kidney) are not 
able to produce VEGF, and therefore its expression 
decreases with the progress of nephropathy [11, 22]. 
Studies of VEGF in patients with diabetic foot syn-
drome shows that the concentration of this factor is 
reduced [14]. In studies performed in the 1990s, de-
creased levels of basic fibroblast growth factor (bFGF), 
VEGF and PDGF in experimental diabetic wounds were 
observed [23–26]. Later studies have confirmed the re-
duced levels of VEGF and PDGF during wound healing 
in diabetic animals [27, 28]. 
More and more attention is being paid to the contri-
bution of the extracellular matrix (ECM) in the process of 
blood vessel formation. ECM is not only the environment 
for the cells. ECM is an environment where there are 
numerous enzymes, cytokines and proteins that enable 
signal transduction [15]. Extracellular matrix compo-
nents are produced by various cells, among others by 
fibroblasts, in response to stimulating factors. Trans-
forming growth factor beta (TGF-b) is one of the factors 
that induce the production of ECM components and 
increase the expression of PDGF, FGF and VEGF, that 
shows its proangiogenic properties [29]. The study of 
endothelial cell cultures and retinal pericytes shows that 
TGF-b may play an important role in the pathogenesis 
of diabetic retinopathy. Van Geest et al. have observed 
that TGF-b has a greater influence on the pericytes than 
endothelial cells and may regulate the synthesis of ECM 
[29]. Despite the fact that the role of TGF-b in the patho-
genesis of diabetic retinopathy is not fully understood, 
in the nephropathy TGF-b is considered to be a factor 
causing basal lamina thickening in the glomerulus [29]. 
Enzymes play no less important a role in angiogenesis 
than next-angiogenic growth factors. One of them is 
heparanase, the function of which has been well studied 
in the pathogenesis of cancers. Heparanase cleaves 
heparan sulphate (HS), the main polysaccharide of 
basement membrane (BM). HS ensures the integrity 
of the basement membrane and controls the activity of 
cytokines, growth factors, through their ECM binding. 
The degradation of HS by heparanase leads to the 
elimination of ECM barriers and the release of bioac-
tive molecules. In this way, heparanase emphasises its 
participation in tissue remodelling, angiogenesis and 
inflammation [13]. Very few studies have shown that 
heparanase activity is increased in the retina neovas-
cularisation. Increased expression of this enzyme was 
observed in STZ-diabetic rats [streptozotocin-diabetic 
rats], that may lead to the development of retinopathy 
[30, 31]. In nephropathy, increased activity of hepara-
nase has also been observed. Shafan et al. reported 
higher levels of heparanase in the plasma and increased 
urinary excretion in patients with T2DM. Furthermore, 
a relationship between heparanase in urine and blood 
glucose has been observed [32]. Rops et al. reported 
increased urinary heparanase activity [33]. Unfortu-
nately, so far there is no data on heparanase in DFS. It is 
well known that abnormal angiogenesis delays diabetic 
wound healing. In 2007, Kawanabe et al. published 
a study that shows that sphingosine-1-phosphate [S1P] 
can accelerate the healing process in mice with induced 
diabetes [34]. Platelets and haematopoietic cells are 
a known source of S1P [35]. Sphingosine phosphate 
is responsible for the migration and proliferation of en-
dothelial cells; it is required for the maturation of blood 
vessels and it is involved in angiogenesis, inflammation, 
wound healing, and thrombosis [34, 35]. S1P transmits 
a signal by specific receptors. It enables the formation 
of N-cadherin-based connections between endothelial 
cells and smooth muscle cells [36]. Thus, S1P contrib-
utes to generating stable blood vessels. Kawanabe et 
al. found that administration of S1P as a subcutaneous 
injection significantly accelerated wound healing in dia-
betic mice compared to control mice (controls did not 
receive S1P injections) [34]. A study by Skoura et al. 
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reported increased sphingosine-1-phosphate recep-
tor (S1P2R) expression in the retina of mice under the 
influence of hypoxia. The researchers suggest that 
hypoxic conditions may contribute to neovascularisa-
tion in the eye [36]. Increased levels of S1P were also 
observed at the early stages of nephropathy [37].  
Among many growth factors, enzymes and angiogenic 
cytokines, also erythropoietin (Epo) is worth noting. Epo 
shows a similar activity to VEGF, but their mechanism 
of action is independent [38]. It has been shown that 
Epo-induced angiogenesis promotes wound healing, 
remodelling myocardial ischaemia and reperfusion in 
the brain [39, 40]. The role of Epo in the pathogenesis 
of diabetic retinopathy is not fully understood. Studies 
have shown elevated levels of Epo in the vitreous [39] 
However, supplementation with Epo in the early stages 
of diabetic retinopathy may have a protective effect on 
neurons and a suppressive effect on hypoxia-induced 
neovascularisation [39]. We have not found any studies 
reporting on Epo in angiogenesis during nephropathy 
and DFS.
The pathogenesis of diabetic vascular complications 
involves a variety of processes; however, angiogenesis 
is closely related to inflammation. Basic fibroblast 
growth factor (FGF-2) is one of the factors that have 
both pro-inflammatory and proangiogenic properties 
[16]. Inflammation may initiate FGF-dependent an-
giogenesis. FGF-2 increases the expression of VEGF, 
cyclooxygenase-2 (COX-2), IL-6 or osteopontin (OPN, 
monocyte chemotactic factor), and activates fibroblasts 
[9, 16]. Fibroblasts also proliferate in response to 
PDGF and TGF-b. They produce erythropoetin and are 
responsible for maintaining extracellular homeostasis 
through the synthesis of ECM components [9]. Fibro-
blasts phenotypic change is observed in patients with 
non-healing wounds. The authors indicate a decreased 
migration and proliferation of fibroblasts isolated from 
ulceration and callus. Moreover, fibroblasts derived 
from diabetic ulcers are characterised by a reduced 
response to angiogenic factors [41, 42]. 
Conclusions
The process of blood vessels formation is very im-
portant for diabetic patients. Insufficient angiogenesis 
contributes to impaired wound healing, while excessive 
vessels formation may lead to blindness. There are 
many well known growth factors, enzymes or cytokines 
involved in angiogenesis. 
Unfortunately, it still remains to be elucidated why 
in a diabetic person both insufficient and excessive an-
giogenesis occurs. This may be an effect of prolonged 
hyperglycaemia on structurally different tissues. Future 
studies will bring new insights into the field of vascular 
diabetic complications.
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